A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression

BACKGROUND: Nucleotide transporters such as human equilibrative nucleoside transporter-1 (hENT1) play a major role in transporting gemcitabine into cells. CO-1.01 (gemcitabine-5′-elaidate) is a novel cytotoxic agent consisting of a fatty acid derivative of gemcitabine, which is transported intracell...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pancreatology
Asıl Yazarlar: Li, D., Pant, S., Ryan, D.P., Laheru, D., Bahary, N., Dragovich, T., Hosein, P.J., Rolfe, L., Saif, M.W., LaValle, J., Yu, K.H., Lowery, M.A., Allen, A., O'Reilly, E.M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4461049/
https://ncbi.nlm.nih.gov/pubmed/25278310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pan.2014.07.003
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller